tbuckley/cabot-search huggingface dataset:
Abstract 16844: Uncoupling of Myocardial Response to Hypoxia in Nonischemic Heart Failure is Associated with Intraventricular Conduction Disease and Reduced Response to Beta-Blockers
Authors: David P Kao, Hannah Tipney, Edward M Gilbert, Lawrence E Hunter, Brian D Lowes, Michael R Bristow
Journal: Circulation (2011)

Background In heart failure patients treated with b-blockers the ability to predict likelihood of improvement in LVEF using clinical features is limited. Molecular profiling may improve individualization of HF prognosis. Hypothesis Knowledge-based analysis of myocardial gene expression identifies pathways relevant to prediction of LVEF improvement in response to beta-blockers. Methods 51 patients with nonischemic dilated cardiomyopathy underwent myocardial biopsy before starting a beta-blocker, and mRNA expression was quantified. Genes associated with LVEF response over 12 months (improvement ≥ 5% and final LVEF ≥35%) were identified (p ≤ 0.001). Top genes were combined with biomedical knowledge in public databases and literature. Combined data were explored to identify pathways of interest. One biologic pathway was selected, and expression of related genes was analyzed. Patients were grouped based on similarities in pathway gene expression, and clinical features were integrated to identify associated phenotypes. Results Three genes associated with response to hypoxia were predictive of LVEF response (HIF-1AN, HK2, BHLHE40). HIF-1α, VEGF, and p53 were identified as up- and down-stream members of this pathway also known to play a role in HF. Analysis of relative expression of HIF-1α, BHLHE40, VEGF, and p53 divided patients into 4 groups (Figure 1). One group was associated with a significantly lower rate of LVEF response (OR 0.16, p=0.01) and a higher likelihood of QRS interval &gt; 120 msec (OR 34.1, p&lt;0.0001). This group had the highest levels HIF-1a expression and lower expression of BHLHE40, VEGF, and p53 relative to HIF-1α compared with other groups. Conclusions Uncoupling of molecular signaling in myocardial response to hypoxia is associated with widened QRS interval and reduced likelihood of LVEF improvement with beta-blocker therapy. This is a group of patients in whom initial treatment with CRT may be indicated.
The Technique of Psychoanalysis.
Authors: Hans von Hattingberg, Arnold Eiloart
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract P17: Abdominal Compression Achieves Similar Survival Rates to Standard Chest Compression Cardiopulmonary Resuscitation
Authors: Theodoros Xanthos, Eleni Koudouna, Eleni Bassiakou, Evaggelia Kouskouni, Ismene Dontas, Despina Perrea, Lila Papadimitriou
Journal: Circulation (2008)

Objectives: Abdominal compression (AC) cardiopulmonary resuscitation (CPR) is a technique in which blood flow during cardiac arrest is produced by compression of the abdominal wall. The aim of the ...
Minding the findings: Let's not miss the message of memory reconsolidation research for psychotherapy
Authors: Bruce Ecker, Laurel Hulley, Robin Ticic
Journal: Behavioral and Brain Sciences (2015)

Abstract That memory reconsolidation is the process underlying decisive, lasting therapeutic change has long been our proposal, and the recognition of its critical role by Lane et al. is a welcome development. However, in our view their account has significant errors due to neglect of research findings and neglect of previous work on the clinical application of those findings.
Abstract 2962: Donor-specific Antibodies Correlate with Events in Heart Transplant Patients
Authors: Biljana Pavlovic-Surjancev, Nilamkumar Patel, James Sinacore, Norma Neuswanger, Brian Susskind, Alain Heroux
Journal: Circulation (2008)

Antibodies (ab) against human leukocyte antigens (HLA) in transplant (tx) recipients are associated with poor outcome. Flow PRA (panel reactive ab) detects non-specific ab against Class I &amp; II HLA (%). New technology detects ab against donor HLA = Donor-Specific Ab (DSA). Experience with DSA in heart tx patients (pts) is limited. Purpose: To evaluate presence of non-specific ab &amp; DSA and to correlate it with events in heart tx pts. Methods : We included all pts with heart tx done Feb 1986-Feb 2008 followed at our ctr with post-tx flow PRA drawn March 2006-Feb 2008 on random sample or event-related sample, ordered at clinician’s discretion. Random sample was drawn during clinic visit or hospital admission not related to graft rejection. Event is defined as hospital admission for suspected graft rejection. There were 277 samples drawn for flow PRA from 93 pts. To reduce bias related to multiple samples from 1 pt we included only 1 sample with highest PRA %. Pts were categorized in 2 groups: PRA ≥ 10% (high) and PRA &lt; 10% (low). Low titer DSA was &lt; 100,000 molecules of equivalent soluble fluorescence units (MESF). Results : Among 93 pts, 27 pts had PRA ≥10% (29%), among which 13 pts had event (14% of 93 pts) and 66 pts had PRA &lt; 10% (71%) among which 3 pts had event (3% of 93 pts). Low PRA Group: Among 66 pts with PRA &lt; 10%, 63 pts had no events (95.5%). Among 66 pts with PRA &lt; 10%, 42 pts had no DSA tested and 24 pts had DSA tested. Among 24 pts with DSA tested, 23 pts had negative DSA and 1 pt had positive low titer DSA (this pt had no event). Three pts with negative DSA had an event; one of them had cross-reactive ab. High PRA Group: 27 pts with PRA≥10% were subcategorized in 2 groups based on the presence or the absence of the event. Group 1(N = 14 (52%)) had no event:8 pts did not have DSA drawn, 5 pts were DSA negative and 1 pt was positive with low titer DSA. Group 2(N = 13 (48%)) had an event:10 pts were DSA positive with high-titer, whereas 3 pts were DSA negative (1 pt had cross-reactive ab to donor-specific antigen). Difference between Groups 1 and 2 was significant by Fisher’s exact test (p &lt; 0.05). Conclusions : Majority of pts hospitalized for suspected rejection (75%) had high-titer positive DSA (62.5%) or cross-reactive ab to donor-specific antigen (12.5%). This study will be basis for future prospective DSA monitoring.
The Level of Oxygen Exchange in Obesity As a Factor In Planning Treatment
Authors: Frank A. Evans
Journal: Annals of Internal Medicine (1931)

Article1 November 1931The Level of Oxygen Exchange in Obesity As a Factor In Planning TreatmentFRANK A. EVANS, M.D., F.A.C.P.FRANK A. EVANS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-5-5-574 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIt is justifiable to consider the excess weight in obesity as inactive storage tissue. We may think of the obese patient as seen, as made up of his ideal weight plus burdensome, useless fat1,2,3. Removal of the excess weight can be accomplished only by burning this fat. This is done by measures which bring about a difference between energy intake and energy output, but which do not throw on the organism unphysiological burdens. Marked lowering of the energy intake can be accomplished safely by radical limitation of diets along physiological principles. Increase of energy output by thyroid medication adds to...References1 MCCLUGAGEBOOTHEVANS HBGFA: Creatinine excretion in abnormal states of nutrition, Am. Jr. Med. Sci., 1931, clxxxi, 349. CrossrefGoogle Scholar2 STRANGMCCLUGAGEEVANS JMHBFA: The nitrogen balance during dietary correction of obesity, Am. Jr. Med. Sci., 1931, clxxxi, 336. CrossrefGoogle Scholar3 EVANS FA: Some factors in metabolism of importance in obesity, Proc. Clim. and Clin. Assoc., 1930, xlvi, 76. Google Scholar4 EVANSSTRANG FAJM: A departure from the usual methods of treating obesity, Am. Jr. Med. Sci., 1929, clxxvii, 339. CrossrefGoogle Scholar5 STRANGMCCLUGAGEEVANS JMHBFA: Further studies in the dietary correction of obesity, Am. Jr. Med. Sci., 1930, clxxix, 687. CrossrefGoogle Scholar6 MEANS JH: Basal metabolism in obesity, Arch. Int. Med., 1916, xvii, 704. CrossrefGoogle Scholar7 STRANGEVANS JMFA: The energy exchange in obesity, Jr. Clin. Invest., 1928, vi, 277. CrossrefGoogle Scholar8 DU BOIS EF: Recent advances in the study of basal metabolism, Jr. Nutrit., 1930, iii, 217. Google Scholar9 STRANGMCCLUGAGE JMHB: The specific dynamic action of a mixed meal in abnormal nutritional states, Am. Jr. Med. Sci., in print. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Pittsburgh, Pa.*From the Western Pennsylvania Hospital, Pittsburgh, Pa.†Presented at the Baltimore meeting of the American College of Physicians, March 26, 1931. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byFettsucht und Magersucht 1 November 1931Volume 5, Issue 5Page: 574-578KeywordsDietFatsObesityOverweightOxygenThyroid ePublished: 1 December 2008 Issue Published: 1 November 1931 PDF downloadLoading ...
Panic, agoraphobia, and vestibular dysfunction
Authors: R G Jacob, J M Furman, J D Durrant, S M Turner
Journal: American Journal of Psychiatry (1996)

Otoneurological abnormalities have been reported in panic disorder. The purpose of this investigation was to determine the prevalence of such findings in panic disorder with and without agoraphobia and to discern whether vestibular dysfunction was associated with specific symptoms.Clinical audiological and vestibular tests were administered to 30 patients with uncomplicated panic disorder (without agoraphobia or with only mild agoraphobia), 29 patients with panic disorder with moderate to severe agoraphobia, 27 patients with anxiety but no history of panic attacks, 13 patients with depressive disorders but no history of anxiety or panic attacks, and 45 normal comparison subjects. Evaluators were blind to subjects' diagnostic group. Quantitative measures of subjects' discomfort with space and motion and of the frequency of certain symptoms between and during panic attacks were obtained. Anxiety state levels were measured during the vestibular tests.Vestibular abnormalities were common in all the groups but most prevalent in the patients with panic disorder with moderate to severe agoraphobia. Vestibular dysfunction was associated with space and motion discomfort and with frequency of vestibular symptoms between, but not during, panic attacks. There were no major differences between the two panic groups in anxiety levels during vestibular testing. There were no significant differences between groups on the audiological component of the test battery. Exploratory data analysis indicated that the constellation of vestibular tests most specific for agoraphobia was one indicating compensated peripheral vestibular dysfunction.Subclinical vestibular dysfunction, as identified by clinical tests, may contribute to the phenomenology of panic disorder, particularly to the development of agoraphobia in panic disorder patients.
Abstract 8566: Regression Pattern of Aortic Lesion after Endovascular Stent-graft Implantation in Patients with Complicated Acute Aortic Syndrome
Authors: Hyunmin Choe, Woo-Ik Jang, Chang Young Kim, Joon Hyung Doh, Jae-Jin Kwak, June Namgung, Sung Yun Lee, Won Ro Lee
Journal: Circulation (2011)

Background: Endovascular aortic repair (EVAR) using stent-graft has been appropriate and valid treatment in selected patients with complicated or progressive acute aortic syndrome (AAS). However, there is few data about regression or change of aortic lesions after EVAR. Methods and Results: From January 2007 to May 2010, 29 patients who underwent EVAR due to complicated or progressive AAS were enrolled. The underlying aortic syndrome included an intramural hematoma (IMH, n = 15), penetrating atherosclerotic ulcer in aortic aneurysm (PAU in AA, n = 9) and Stanford type B aortic dissection (AD, n = 5). We analyzed the changes in maximal diameter of aorta, minimal diameter of inner lumen and maximal thickness or lumen size of hematoma, aneurysm and dissection before and after EVAR using 64-multidetector computed tomography (MDCT). Then, we defined &gt; 75% of shrinkage in maximal thickness or size of pathologic lesions after EVAR as complete, 25-75% as partial and &lt; 25% as no regression. The follow-up 64-MDCT data was obtained from 12-month after EVAR (mean 10.8 ± 1.1 months), and the rate of follow-up 64-MDCT was 89.7%. Lesion characteristics and changes after EVAR were described in Table. Conclusion: EVAR in complicated or progressive AAS lesions promotes the regression of the main aortic disease through stabilizing further evolution of underlying pathology and maintaining inner luminal space. Also, EVAR achieves the high rate of complete regression in patients with IMH.
Abstract 1952: ABCA1 Deficency Diminishes Dysfunctional HDL And Inhibits Early Atherosclerotic Lesion Development In SR-BI Knockout Mice
Authors: Ying Zhao, Ruud Out, Dan Ye, Theo J Van Berkel, Miranda Van Eck
Journal: Circulation (2008)

Objective: ABCA1 and SR-BI play an essential role in reverse cholesterol transport (RCT) from macrophages in the arterial wall to the liver. The aim of this study was to investigate the effect of combined total-body ABCA1 and SR-BI deficiency on lipoprotein metabolism and atherosclerosis. Methods &amp; Results: ABCA1/SR-BI double knockout (dKO), ABCA1 KO (AKO), SR-BI KO (SKO), and wildtype (WT) littermates were fed an atherogenic diet for 10 weeks to induce atherosclerosis. Under these conditions, SR-BI deficiency leads to largely increased serum cholesterol (C) levels (SKO: 470±68 mg/dL vs WT: 181±9 mg/dL, p&lt;0.001), due to an impaired removal of HDL-C and VLDL-C, while hampered HDL production in AKO mice resulted in cholesterol levels of only 23±4 mg/dL (p&lt;0.0001). In dKO mice, HDL-C was similarly low as in single AKO mice. Total serum cholesterol levels, however, were 3.8-fold (p&lt;0.001) higher, due to increased VLDL-C levels. Interestingly, more extreme foam cell accumulation was observed in the peritoneal cavity of dKO mice ((30±6%, p&lt;0.01), as compared to WT (1.7±0.2%), SKO (2.5±0.3%), and AKO (5±2%) mice. Combined deletion of ABCA1 and SR-BI thus induces macrophage foam cell formation in vivo . The accumulation of HDL-C and VLDL-C in SKO mice dramatically induced atherosclerotic lesion formation (206±16x10 3 μm 2 vs 12±2x10 3 μm 2 for WT mice, p&lt;0.001)), while lesions were only 33±12x10 3 μm 2 (p&lt;0.05) in AKO and 51±19x10 3 μm 2 (p&lt;0.01) in dKO mice with low HDL-C levels. Thus, despite enhanced foam cell formation in dKO mice, ABCA1 deletion reduces the atherosclerosis susceptibility of SKO mice. Next, the serum atherogenicity was tested by incubation of RAM cells with 3% serum of different types of mice. Serum from SKO mice induced more extreme foam cell formation (89±2%, p&lt;0.001), compared to serum from WT (31±3%), AKO (2.3±0.1%), and dKO (3.1±0.5%) mice. Interestingly, this effect highly correlated with both HDL-C (r=0.98, p&lt;0.0001) and VLDL/LDL-C levels (r=0.96, p&lt;0.0001). Conclusion: Total-body ABCA1 deficiency inhibits early atherosclerotic lesion development in SR-BI KO mice, which might be attributable to reduced circulating levels of pro-atherogenic HDL. Furthermore, both SR-BI and ABCA1 are essential for maintaining HDL-mediated RCT.
Focus on emotion as a catalyst of memory updating during reconsolidation
Authors: Maria Stein, Kristina Barbara Rohde, Katharina Henke
Journal: Behavioral and Brain Sciences (2015)

Abstract We share the idea of Lane et al. that successful psychotherapy exerts its effects through memory reconsolidation. To support it, we add further evidence that a behavioral interference may trigger memory update during reconsolidation. Furthermore, we propose that – in addition to replacing maladaptive emotions – new emotions experienced in the therapeutic process catalyze reconsolidation of the updated memory structure.
Abstract 17352: Incidence and Predictors of Stroke in Patients with Chronic Heart Failure: Does Left Ventricular Function Matter? Insights From the CHARM Program
Authors: Davide Castagno, Hicham Skali, Madoka Takeuchi, Karl Swedberg, Salim Yusuf, Christopher B Granger, Marc A Pfeffer, John J McMurray, Scott D Solomon
Journal: Circulation (2011)

Objectives Patients with heart failure and reduced ejection fraction (HF-REF) are at increased risk of stroke, with some studies suggesting an inverse association between ejection fraction (EF) and stroke risk. The rate of stroke in simultaneously enrolled patients with HF-REF and preserved EF (HF-PEF) has not been reported and the predictors of stroke in a contemporary population of patients with HF are unknown. The Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) program, which included patients with a wide range of EF, provided a unique opportunity to examine these questions about stroke in HF. Methods We evaluated risk factors for stroke with multivariable Cox proportional hazard regression analysis using forward- and backward-stepwise selection of candidate variables, with gender, history of hypertension, EF and randomized treatment (i.e. candesartan) forced into the model. Results Of the 7599 participants in CHARM, 287 (3.8%) experienced a fatal or nonfatal stroke during a median follow-up of 37.7 months. The stroke rate was 1.3 (95% CI=1.1-1.5) and 1.4 (95% CI=1.2-1.7) per 100 pt yrs in subjects with reduced and preserved EF respectively. The 5 strongest predictors of stroke (ranked by chi-square value) were: older age, previous stroke, higher systolic blood pressure, diabetes and atrial fibrillation on baseline ECG; other independent predictors are shown in the figure. Univariate predictors not retained in the multivariable model were: history of hypertension, NYHA class III or IV, baseline oral anticoagulant use, previous coronary bypass surgery, current smoking, signs of HF, diuretic use and female sex; none of the other forced variables were predictive in either the univariate or multivariable models. Conclusions The rate of stroke is similar in patients with HF-REF and HF-PEF. Even in this relatively normotensive population, higher systolic BP was associated with greater stroke risk.
Post-Transplant Cyclophosphamide Following Myeloablative Peripheral Blood Stem Cell Transplantation: A Single Institutional Experience
Authors: Racquel Innis-Shelton, Donna Salzman, Antonio Di Stasi, Lawrence S. Lamb, Melissa Gazi, Lisa Williams, Luciano J Costa, Harry Erba, Shin Mineishi, Ayman Saad
Journal: Blood (2014)
Abstract 16217: Influence of Older Age on Adverse Outcomes in Heart Failure
Authors: Rashmee U Shah, Jing Rong Yang, Sue Hee Hung, Mark A Hlatky, Alan S Go
Journal: Circulation (2011)

Background Reasons for worse outcomes among older heart failure (HF) patients are unclear. We evaluated the contributions of non-modifiable and modifiable factors in explaining variations in advers...
Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association
Authors: R. M A Hirschfeld, P. J. Clayton, I. Cohen, J. Fawcett, P. Keck, J. McClellan, S. McElroy, R. Post, A. Satloff, J. S. McIntyre, S. C. Charles, K. Z. Altshuler, W. H. Ayres, B. Blinder, L. Dickstein, G. H. Flamm, J. M. Kent, S. Miller, L. Moench
Journal: American Journal of Psychiatry (1994)
Clinical activity and safety of the histone deacetylase inhibitor MGCD0103: Results of a phase I study in patients with leukemia or myelodysplastic syndromes (MDS)
Authors: G. Garcia-Manero, M. Minden, Z. Estrov, S. Verstovsek, W. M. Newsome, G. Reid, J. Besterman, Z. Li, L. Pearce, R. Martell
Journal: Journal of Clinical Oncology (2006)

6500 Background: MGCD0103 is a novel inhibitor of human histone deacetylases (HDACs), with selectivity for the cancer-associated isoforms of class I HDACs. Deacetylation of histones by HDACs is postulated to inactivate tumour suppressor genes leading to neoplastic transformation, and therefore inhibition of this enzyme may result in antineoplastic activity. Methods: To study the safety and activity of MGCD0103, we have developed a phase I open-label dose escalation study of MGCD0103 administered orally, three-times weekly in patients with leukemia or MDS, with the primary endpoints being the determination of the maximum tolerated dose (MTD) and the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of MGCD0103. Eligibility criteria included appropriate performance status and renal and hepatic functions. Patients with relapsed/refractory leukemia or MDS and older patients with untreated AML/MDS were eligible. Results: Twenty patients have been enrolled at four dose levels (20, 40, 80 and 60 mg/m 2 ) so far. Their characteristics are: median age 60 years (range 33–76); the majority of patients so far treated have AML; median number of prior therapies is 1 (range 0–3). Most patients had complex cytogenetics. MGCD0103 has been well tolerated at doses below 80 mg/m 2 . The MTD has been reached, with 3 out of 4 patients at a dose of 80 mg/m 2 developing grade 3 toxicity, mainly fatigue, nausea, vomiting or diarrhea. Grade 2 toxicities include anorexia, constipation, dehydration. The median number of courses is 1 (range 1 to 6). As of January 2006, 7 patients are on study. PK evaluations show dose-dependent exposure. Analysis of peripheral blood cell HDAC activity indicates that HDAC inhibition occurs in all patients in a dose-dependent manner. Two patients with multiple relapsed/refractory acute myelogenous leukemia, and one with MDS have achieved a complete marrow response (blasts less than 6%). Of importance, maximal HDAC inhibition was observed in those patients at the time of best response. Conclusions: Single-agent MGCD0103 has clinical activity and is well tolerated at doses below 80 mg/m 2 orally three times a week in patients with advanced leukemia. No significant financial relationships to disclose.